Small-molecule inhibitors of the p53-HDM2 interaction for the treatment of cancer
The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The hdm2 oncogene product, HDM2 (also known as MDM2), is an ubiquitin protein ligase that suppresses the transcriptional activity of the tumor suppressor p53 and promotes its degradation. Approximately 50% of all human tumors harbor mutations or deletions in the TP53 gene. In the remaining half of all human cancers that express the wild-type protein, aberrations of p53 regulators such as HDM2 account for p53 inhibition. Therefore, small-molecule inhibitors of the HDM2-p53 protein-protein interaction appear to offer an attractive strategy for cancer therapy. OBJECTIVE: This review focuses on recent progress in the field of small-molecule inhibitors of the p53-HDM2 protein-protein interaction for the treatment of cancer. RESULTS/CONCLUSION: The development of pharmacological inhibitors has been challenging. Although many small-molecule HDM2 inhibitors have shown potent in vitro activity, only a limited number of compounds have displayed acceptable pharmacokinetic properties for in vivo evaluation. To date, the most studied chemotypes have been cis-imidazolines (e.g., Nutlins), benzodiazepines (BDPs) and spiro-oxindoles. The cis-imidazolines were the first reported potent, selective small-molecule inhibitors of the p53-MDM2 interaction, and continue to show therapeutic potential. Additionally, p53-based strategies involving inhibition of MDM2-mediated p53 ubiquitylation and restoration of DNA-binding activity of mutant p53 protein, as well as combination therapies, will be briefly described. Finally, a structurally distinct chemotype currently in Phase I clinical trials will be presented.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661 · cited 4×
“In human cancer cell lines with WT p53 (HCT116 and RKO: colon; SJSA-1: osteosarcoma), Compounds 18 – 20 were shown to have good cell permeability and caused dose-dependent accumulation of WT p53 that resulted in elevation of MDM2 and p21 proteins [83] .”
BackgroundInfluentialMdm2 promotes the rapid degradation of p53
Haupt, Y., Maya, R., Kazaz, A., & Oren, M. (1997) · Nature · doi:10.1038/387296a0 · Cited by 4,506 · cited 1×
“Increased MDM2 levels regulate p53 activity in three ways [35-39] : i) MDM2 binds to the N-terminal domain of p53 (also known as the BOX1 domain), blocking transcriptional activity; ii) MDM2 induces nuclear export; iii) MDM2 stimulates degradation of p53 by the E3 ubiquitin ligase/proteasome pathway.”
BackgroundRegulation of p53 stability by Mdm2
Kubbutat, M. H. G., Jones, S. N., & Vousden, K. H. (1997) · Nature · doi:10.1038/387299a0 · Cited by 3,312 · cited 1×
“Increased MDM2 levels regulate p53 activity in three ways [35-39] : i) MDM2 binds to the N-terminal domain of p53 (also known as the BOX1 domain), blocking transcriptional activity; ii) MDM2 induces nuclear export; iii) MDM2 stimulates degradation of p53 by the E3 ubiquitin ligase/proteasome pathway.”
BackgroundStructure of the MDM2 Oncoprotein Bound to the p53 Tumor Suppressor Transactivation Domain
Kussie, P. H., Gorina, S., Marechal, V., Elenbaas, B., Moreau, J., Levine, A. J., & Pavletich, N. P. (1996) · Science · doi:10.1126/science.274.5289.948 · Cited by 2,206
Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53
Honda, R., Tanaka, H., & Yasuda, H. (1997) · FEBS Letters · doi:10.1016/s0014-5793(97)01480-4 · Cited by 1,951
Amplification of a gene encoding a p53-associated protein in human sarcomas
Oliner, J. D., Kinzler, K. W., Meltzer, P. S., George, D. L., & Vogelstein, B. (1992) · Nature · doi:10.1038/358080a0 · Cited by 1,949
Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53
de Oca Luna, R. M., Wagner, D. S., & Lozano, G. (1995) · Nature · doi:10.1038/378203a0 · Cited by 1,420 · cited 1×
“It was demonstrated that mice lacking the MDM2 gene are embryonic-lethal (die early in development), but this lethality is fully rescued by deletion of p53, suggesting that the activity of p53 is regulated by MDM2 [23,24] .”
BackgroundRegulating the p53 pathway: in vitro hypotheses, in vivo veritas
Toledo, F., & Wahl, G. M. (2006) · Nature reviews. Cancer · doi:10.1038/nrc2012 · Cited by 1,286
Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53
Jones, S. N., Roe, A. E., Donehower, L. A., & Bradley, A. (1995) · Nature · doi:10.1038/378206a0 · Cited by 1,280
Bond, G. L., Hu, W., Bond, E. E., Robins, H., Lutzker, S. G., Arva, N. C., Bargonetti, J., Bartel, F., Taubert, H., Wuerl, P., et al. (2004) · Cell · doi:10.1016/j.cell.2004.11.022 · Cited by 1,265
Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound
Bykov, V. J. N., Issaeva, N., Shilov, A., Hultcrantz, M., Pugacheva, E., Chumakov, P., Bergman, J., Wiman, K. G., & Selivanova, G. (2002) · Nature Medicine · doi:10.1038/nm0302-282 · Cited by 1,067
Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy
Tovar, C., Rosinski, J., Filipovic, Z., Higgins, B., Kolinsky, K., Hilton, H., Zhao, X., Vu, B. T., Qing, W., Packman, K., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0507493103 · Cited by 708
Ding, K., Lu, Y., Nikolovska-Coleska, Z., Wang, G., Qiu, S., Shangary, S., Gao, W., Qin, D., Stuckey, J., Krajewski, K., et al. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm051122a · Cited by 702 · cited 3×
“Substitution of the secondary amide with aminoethylmorpholine, and incorporation of a fluorine atom at the 2-position of the phenyl ring, yielded the significantly more potent inhibitor 16 (also known as MI-63) with a K i value of 3 nM in the FP-based binding assay ( Figure 5 ) [81] .”
BackgroundShangary, S., Qin, D., McEachern, D., Liu, M., Miller, R. S., Qiu, S., Nikolovska-Coleska, Z., Ding, K., Wang, G., Chen, J., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0708917105 · Cited by 660 · cited 4×
“for 14 days), inhibited tumor growth by 75% compared with vehicle control [82] .”
BackgroundInfluentialStructure-based design of potent non-peptide MDM2 inhibitors
Ding, K., Lu, Y., Nikolovska-Coleska, Z., Qiu, S., Ding, Y., Gao, W., Stuckey, J., Krajewski, K., Roller, P. P., Tomita, Y., et al. (2005) · Journal of the American Chemical Society · doi:10.1021/ja051147z · Cited by 657 · cited 3×
“5 μM for cell growth inhibition, demonstrating its selectivity between cancerous and normal cells possessing WT p53 [80] .”
BackgroundMDMX: a novel p53‐binding protein with some functional properties of MDM2.
Shvarts, A., Steegenga, W. T., Riteco, N., van Laar, T., Dekker, P., Bazuine, M., van Ham, R. C., van der Houven van Oordt, W., Hateboer, G., van der Eb, A. J., et al. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00919.x · Cited by 648 · cited 1×
“Another critical regulator of p53 is MDMX (also known as MDM4), a structural homolog of MDM2, which is overexpressed in 10 – 20% of various tumors, again resulting in suppression of p53 activity [25-27] .”
BackgroundMDM2 inhibitors for cancer therapy
Vassilev, L. T. (2007) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2006.11.002 · Cited by 532 · cited 4×
“Protein–protein interactions (PPIs) are responsible for important biological processes such as cell growth and differentiation, intracellular signaling and programmed cell death (apoptosis) [1-17] .”
BackgroundInfluentialParant, J., Chavez-Reyes, A., Little, N. A., Yan, W., Reinke, V., Jochemsen, A. G., & Lozano, G. (2001) · Nature Genetics · doi:10.1038/ng714 · Cited by 517 · cited 1×
“Like MDM2, a knockout of the MDMX gene in mice was shown to be embryonic-lethal, and the MDMX and p53 double knockout was shown to be viable [28] .”
BackgroundDesign of a synthetic Mdm2-binding mini protein that activates the p53 response in vivo
Böttger, A., Böttger, V., Sparks, A., Liu, W.-L., Howard, S. F., & Lane, D. P. (1997) · Current Biology · doi:10.1016/s0960-9822(06)00374-5 · Cited by 363 · cited 3×
“Initial experiments involving screening of phage display peptide libraries identified the 6-mer peptide (Thr18-Phe-Ser-Asp-Leu-Trp23), which inhibited the p53–MDM2 interaction with a modest IC 50 of 700 μM [48-50] .”
BackgroundRayburn, E., Zhang, R., He, J., & Wang, H. (2005) · Current Cancer Drug Targets · doi:10.2174/1568009053332636 · Cited by 265 · cited 1×
“Indeed, HDM2 is overexpressed in many human tumors, particularly sarcomas, containing WT p53; it is associated with increased metastasis, resulting in accelerated cancer progression [30-34] .”
BackgroundMDM2 and MDM4: p53 regulators as targets in anticancer therapy
Toledo, F., & Wahl, G. M. (2007) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2007.03.022 · Cited by 261
PRIMA-1MET synergizes with cisplatin to induce tumor cell apoptosis
Bykov, V. J. N., Zache, N., Stridh, H., Westman, J., Bergman, J., Selivanova, G., & Wiman, K. G. (2005) · Oncogene · doi:10.1038/sj.onc.1208419 · Cited by 252
MDMX overexpression prevents p53 activation by the MDM2 inhibitor Nutlin
Hu, B., Gilkes, D. M., Farooqi, B., Sebti, S. M., & Chen, J. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.c600147200 · Cited by 236
Levels of HdmX expression dictate the sensitivity of normal and transformed cells to Nutlin-3
Patton, J. T., Mayo, L. D., Singhi, A. D., Gudkov, A. V., Stark, G. R., & Jackson, M. W. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3832 · Cited by 189 · cited 1×
“Prior studies have successfully demonstrated that overexpressed MDMX can block the ability of cis imidazolines to induce apoptosis, thus limiting the effectiveness of cis -imidazoline-based therapy [98-100] .”
BackgroundAmbrosini, G., Sambol, E. B., Carvajal, D., Vassilev, L. T., Singer, S., & Schwartz, G. K. (2007) · Oncogene · doi:10.1038/sj.onc.1210136 · Cited by 163 · cited 2×
“By contrast, and as described earlier in this paper, the combination of 20 and 27 with various cytotoxic agents demonstrated additive or synergistic effects in vivo [85-96] .”
BackgroundHdmx modulates the outcome of p53 activation in human tumor cells
Wade, M., Wong, E. T., Tang, M., Stommel, J. M., & Wahl, G. M. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m605405200 · Cited by 163
Efeyan, A., Ortega-Molina, A., Velasco-Miguel, S., Herranz, D., Vassilev, L. T., & Serrano, M. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0200 · Cited by 140 · cited 2×
“By contrast, and as described earlier in this paper, the combination of 20 and 27 with various cytotoxic agents demonstrated additive or synergistic effects in vivo [85-96] .”
Background
Cited by
The role of p53 in cancer drug resistance and targeted chemotherapy
Hientz, K., Mohr, A., Bhakta-Guha, D., & Efferth, T. (2017) · Oncotarget · doi:10.18632/oncotarget.13475 · Cited by 587
Peptides Containing β-Amino Acid Patterns: Challenges and Successes in Medicinal Chemistry
Cabrele, C., Martinek, T. A., Reiser, O., & Berlicki, Ł. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm5010896 · Cited by 368
p53 mutations in colorectal cancer- molecular pathogenesis and pharmacological reactivation
Li, X.-L. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i1.84 · Cited by 367
History of protein–protein interactions: From egg‐white to complex networks
Braun, P., & Gingras, A. (2012) · PROTEOMICS · doi:10.1002/pmic.201100563 · Cited by 308
Atomic Analysis of Protein-Protein Interfaces with Known Inhibitors: The 2P2I Database
Bourgeas, R., Basse, M.-J., Morelli, X., & Roche, P. (2010) · PLoS ONE · doi:10.1371/journal.pone.0009598 · Cited by 126
“Based on this new focus, it is now more and more commonly accepted that protein-protein complexes are an important class of therapeutic targets [2].”
Background
Metadata
- Authors
- Patel, S., & Player, M. R.
- Venue
- Expert Opinion on Investigational Drugs
- Publisher
- Informa Healthcare
- Published
- 2008-11-03
- Volume
- 17
- Issue
- 12
- Pages
- 1865-1882
- ISSN
- 1354-3784 (ISSN-L)
- 1744-7658
- OpenAlex
- W2060291052
- Cited by
- 99
- References
- 27
- FWCI
- 4.16
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.